RealNose.ai

RealNose.ai is transforming scent into a powerful diagnostic tool, leveraging biosensors and AI to replicate the unmatched olfactory abilities of dogs for various diagnostic applications, beginning wi

RealNose.ai has achieved significant momentum across clinical, defense, and funding domains. We have initiated collaboration discussions with the Cleveland Clinic to explore pilots for prostate, breast, and bladder cancer detection. Internationally, we were selected into the NATO DIANA Accelerator and Grant Program, validating our dual-use potential. We also secured TEVV (Test & Evaluation/Validation & Verification) funding for sarin gas detection, strengthening our defense applications. On the research side, we were awarded an STTR grant with MIT to advance our biosensing technology. In paral

Prostate cancer detection today is inefficient, invasive, and costly. Current tools like PSA tests have low specificity—up to 75% of elevated results are false positives—leading to unnecessary, painful biopsies and repeated diagnostic cycles. Biopsies themselves can cause severe complications and often yield uncertain results. This creates a “diagnostic treadmill” that frustrates patients, wastes clinical resources, and drives up healthcare costs. RealNose.ai is solving this by developing a non-invasive, highly accurate, and cost-effective diagnostic platform powered by biosensors and AI, star

RealNose.ai has developed the world’s first biomachine olfaction platform—a system that replicates the mammalian sense of smell using stabilized olfactory receptor proteins combined with advanced AI. Our device “sniffs” volatile organic compounds (VOCs) from samples such as urine, breath, or air and detects disease-specific scent patterns with high sensitivity and specificity. Starting with prostate cancer, our solution provides a non-invasive, fast, and accurate diagnostic tool, eliminating reliance on invasive biopsies. Over time, the platform expands to multiple cancers, neurological diseas

RealNose.ai operates on a hybrid recurring revenue model combining device-as-a-service subscriptions and per-test fees. Diagnostic centers and primary care providers subscribe to our platform at $1,500/month (covering biochip replacements and cloud infrastructure). On top of that, each screening test carries a $20 fee to the provider, who may charge patients or insurers ~$50, ensuring margins for clinical adoption. Long term, we will also generate revenue through strategic partnerships, data licensing for pharmaceutical and biotech R&D, and potential dual-use applications in defense and safety

We have successfully completed NYU Stern’s Endless Frontier Labs (EFL) Digital Health Track, where we refined our strategy, developed prototypes, and built key industry partnerships. In addition, we were selected by NATO’s DIANA Accelerator & Grant Program, a highly competitive program (74 out of 2600 companies, 2.8% acceptance) focused on dual-use technologies, where we are exploring defense and security applications such as chemical weapon detection.